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Oxidative stress and abnormally high levels of reactive oxygen species play an essential role 
in the pathogenesis and progression of inflammatory bowel disease (IBD). Oxidation-
responsive nanoparticles (NPs) are formulated from a phenylboronic esters-modified dextran 
(OxiDEX) that degrades selectively in response to hydrogen peroxide (H2O2). OxiDEX NPs 
are coated with chitosan and encapsulated in a pH-sensitive polymer to produce nano-in-
micro composites. The microparticles are spherical with homogeneous particle size (53 ± 3 
μm) and maintain integrity at acidic pH, preventing the premature release of the NPs in 
gastric conditions. The degradation of NPs is highly responsive to the level of H2O2, and the 
release of the drug is sustained in the presence of physiologically relevant H2O2 
concentrations. The presence of chitosan on the particles surface significantly enhances NPs 
stability in intestinal pH and their adhesion on the intestinal mucosa. Compared to a 
traditional enteric formulation, this formulation shows ten-fold decreased drug permeability 
across C2BBe1/HT29-MTX cell monolayer, implying that lower amount of drug would be 
absorbed to the blood stream and, therefore, limiting the undesired systemic side effects. 
Based on these results, a successful nano-in-micro composite for targeted therapy of IBD was 







































































Stimuli-responsive materials can undergo chemical structure change in response to 
environmental stimuli, such as enzymes, light, pH, temperature, ionic strength and various 
chemical species.[1] Advances in polymer science have led to the development of several 
novel reactive oxygen species (ROS)-responsive materials in the last few years. For example, 
the introduction of arylboronic moieties to common polymers such as poly amino-esters,[2] 
polyesters,[3] cyclodextrins,[4] polycarbonates[5] and PEG-lipid conjugate[6] provides specific 
sensitivity towards hydrogen peroxide (H2O2), making these polymers very attractive for the 
development of oxidation-sensitive systems. Within this group, an oxidation-sensitive dextran 
(OxiDEX) can be prepared by a simple modification of the hydroxyl groups of dextran, 
resulting in a responsive and biocompatible material, thus very promising for biomedical 
applications. [7] Drug delivery systems based on ROS-responsive polymers can be applied for 
various therapeutic purposes, as they represent a promising smart delivery vehicle for 
pathological disorders characterized by ROS overproduction, including cancers and 
inflammatory diseases,[8] such as inflammatory bowel disease (IBD).  
IBD is a chronic inflammation of the gastrointestinal (GI) tract[9] and the therapy is based on 
daily administration of high doses of aminosalicylates, antibiotics, corticosteroids, and 
immuno-suppressive agents. Traditional formulations for IBD present high inter-patient 
variability[10] and several side effects due to systemic drug absorption.[11,12] A disease-targeted 
strategy is desired for IBD treatment, because it allows to target the drug directly to the site of 
action (inflammation) and achieve a controlled drug release, minimizing the unspecific 
absorption and subsequent systemic adverse effects. Oxidative stress plays an essential role in 
the pathogenesis and progression of IBD,[13] and diseased sites present abnormally high ROS 
level, as confirmed by biopsies of tissues taken from IBD patients showing from 10- to 100-





































































localized at sites of intestinal inflammation can be exploited as a selective feature to target the 
delivery system, and avoid the release of the drug in the healthy tissue.[16,17] Accordingly, we 
identified the excessive generation of ROS as a disease-specific triggering mechanism to 
design a responsive drug delivery system. Nano-sized delivery systems have been recognized 
as a promising strategy for IBD treatment, because of their preferential accumulation in the 
inflamed regions of the intestine.[18] Additionally, nanoparticles (NPs) provide the potential of 
tailoring drug properties, including solubility, stability, and release behavior and their surface 
can be easily modified in order to introduce targeting-ligands or adjust surface characteristics 
(e.g., surface charge or adhesive properties). 
Therefore, considering the potential of recently synthesized ROS-responsive polymers and the 
advantages of nano-sized systems in IBD treatment, it is important to evaluate these 
biomaterial for the development of smart high-precision medicines. The aim of this research 
is the development of an advanced oral drug delivery system able to meet multiple demands: 
protection of the responsive NPs against harsh GI environments, prevention of premature drug 
release and achievement of targeted local drug delivery to the diseased sites with limited 
systemic absorption. For this purpose, we designed a nanoplatform based on OxiDEX NPs to 
achieve an oxidation-responsive drug delivery, externally modified with chitosan (CS), 
known for its mucoadhesive properties. Mucoadhesion can be an additional advantage for 
IBD targeting as it promotes better contact with the mucosal surface and reduces the clearance 
of nanocarriers when the intestinal motility is increased, which is common in IBD, helping to 
maintain high local concentration of drug.[19] Rifaximin (RIF), an intestine-specific antibiotic 
successfully used in inducing remission of IBD,[20,21] was chosen as model drug. NPs were 
then encapsulated by microfluidics in hydroxypropyl methylcellulose acetate succinate 
(HPMCAS), a pH-responsive polymer, to produce nano-in-micro structured particles[22,23]. 





































































GI tract (e.g., acid pH of the stomach) and to release them in the intestine, closer to the 
targeted site. Thereafter, upon triggering by abnormally elevated ROS levels, the OxiDEX 
NPs will selectively release RIF to the inflamed tissues.  
In this study OxiDEX has been combined for the first time with a pH-sensitive material to 
obtain a nano-in-micro composite with sequential responsive-behaviour to pH and ROS. 
 
2. Results and discussion 
2.1. Characterization of nanoparticles 
A H2O2-responsive material (OxiDEX) was synthesized and used to prepare NPs, which were 
subsequently coated with CS. The preparation procedure of the particles is schematically 
shown in Figure 1a. The NMR spectrum of OxiDEX (Figure S1a) and the NMR study of the 
polymer degradation after treatment with and without H2O2 (Figure S1ab) confirmed the 
successful synthesis of the polymer.[7] 
 
 
Figure 1. (a) Scheme of the production procedure of NPs and CS-NPs and schematic 
illustration of the fabrication process of the nano-in-micro composites by microfluidics:  NPs 
and CS-NPs were encapsulated in MF grade of HPMCAS (MF) to form, respectively, the 
composites (NPs@MF and CS-NPs@MF). NPs or CS-NPs were dispersed in an ethyl acetate 
solution of MF, which served as inner oil fluid. The outer continuous fluid was 2% w/v P-407 






































































The size and polydispersity index (PDI) of OxiDEX NPs were firstly evaluated by dynamic 
light scattering (DLS). The hydrodynamic average size was 50-200 nm (Figure 2a), and it 
was not affected by the CS coating. Moreover, a relatively similar particle size distribution 
was observed for NPs and CS-NPs (Figure S2); however, a slightly wider particle size 
distribution was detected in the case of CS-NPs, due to the presence of CS layer on the 
particle surface, which led to a size distribution moved towards higher values and to an 
increased polydispersity. This trend was confirmed by a small increase in the PDI (Figure 2a), 
which passed from 0.303 to 0.363 after CS coating in the case of unloaded particles. Similarly, 
for RIF-loaded particles the PDI increased from 0.344 to 0.412 after CS coating. The presence 
of CS on the particle surface was confirmed by the measurement of zeta-potential, that 
changed from negative (−24.4 ± 1.7 mV) to positive (+11.6 ± 0.5 mV) (Figure 2b), because 
of the positively charged amino groups of CS. The morphology of OxiDEX particles was 
studied by transmission electron microscopy (TEM). TEM images of single particles (Figure 
1b,c) and of multiple particles (Figure S3) show highly spherical particles in case of uncoated 
NPs, while a more irregular particle shape due to surface covering of CS was noticed for CS-
NPs. The size of dried particles observed in TEM images was slightly larger than the average 
hydrodynamic diameter obtained from the DLS experiment, but still consistent with the DLS 
results if observing the size distribution (Figure S2). Fourier transform infrared (FTIR) 
spectroscopy results are reported in Figure 2c and Figure S4 (wavenumbers 2000-650 cm-1). 
Dextran showed characteristic bands at 3400, 2923, and 915 cm−1, attributed to O-H bonds, 
C−H bonds, and the α-glucopyranose ring, respectively.[24] After the boronic ester 
modification, we observed the presence of new bands at 1640, 1610 and 1540 cm-1 due to the 
C-H stretching vibrations of the aromatic groups. Moreover, after modification, the broad 
band at 3400 cm-1 due to dextran hydroxyl groups was markedly reduced and an extra strong 





































































formed ester groups. These characteristic bands of OxiDEX can be found with minor shift in 
the NPs. Comparing the spectra of NPs before and after CS coating, in the CS-NPs extra 
bands (1541, 1560, 1653, 1676 and 1684 cm-1) appeared, which were absent in the spectrum 
of NPs. In particular, the bands ranging from 1510 to 1650 cm−1 represent a distinctive feature 
of CS and may be attributed to its amide groups.[25] In this region, the two strongest signals 
(1676 and 1684 cm-1) can be found in the spectrum of CS-NPs. In addition, compared to the 
FTIR spectrum of NPs, the carbonyl band (1650 cm-1) was shifted to higher wavenumbers 
(1653 cm−1) after CS coating. This strong band at 1653 cm-1, which can be seen in the 
spectrum of pure CS, is characteristic of the polymer and attributed to the –C=O stretching 
vibration of its secondary amide.[25b,26] 
 
Figure 2. (a) Size and PDI and (b) zeta-potential of NPs and CS-NPs both unloaded and 
loaded with RIF. (c) FTIR spectra of dextran (DEX), OxiDEX, NPs, CS-NPs and pure CS. (d) 
Evolution of the nanoparticle size and polydispersity index (PDI) during incubation in 






































































The RIF loading in NPs was 3.3 ± 0.1% with an encapsulation efficiency of 6.6%; after CS 
coating, the drug loading degree was 2.9 ± 0.2%. Similar loading degree has been reported in 
hyaluronan-based NPs prepared by nanoprecipitation method.[27] Since the NPs are designed 
to deliver the drug locally on the intestinal membrane, the formulation needs to be stable the 
time necessary to reach the inflamed mucosa and to be degraded by the local ROS. Hence, the 
colloidal stability of RIF NPs and RIF CS-NPs was studied in a medium simulating intestinal 
conditions (Figure 2d). The average sizes of NPs showed fluctuations between 110 and 230 
nm and the PDI, approximately 0.4, had also moderate variations. We found that the presence 
of CS on the NPs surface led to more stable particle size and lower PDI, which was around 
0.3. Comparing these results with the ones obtained in MilliQ-water (Figure 2a) we can 
deduce that in the presence of saline buffer, the OxiDEX particles were less stable than in 
water. However, after CS coating, the stability in buffer increased significantly. In particular, 
the average size was stable at 180 nm for the first 120 min, and only a small increasing in size 
(to around 200 nm) was observed in the third hour, suggesting that the NPs’ tendency to 
aggregate in buffer was attenuated by the addition of CS coating. 
 
2.2. H2O2-responsive degradation of NPs 
The hydrolysis of OxiDEX NPs was examined in PBS containing various concentrations of 
H2O2, by measuring the amount of encapsulated drug released in the buffer after particle 
degradation (Figure 3a). Concentrations ranging from 0.1 to 1.0 mM of H2O2 were chosen 
basing on the sensitivity of OxiDEX, which had previously showed degradation when 
incubated with H2O2 1.0 mM.
[7] In 1 h, more than 60% of RIF was released with 1.0 mM of 
H2O2 and even at low H2O2 concentration (100 µM), still more than 14% of the drug was 
released by the end of the test. NPs were not degraded in PBS alone (RIF released < 1% after 
6 h). The appearance of NPs suspensions confirmed the H2O2 dependent degradation of the 





































































observed, whereas a yellowish colloidal solutions could still be observed after 6 h of 
incubation in PBS (Figure 3b), indicating the presence of solid NPs. These results proved that 
degradation of OxiDEX NPs was highly responsive to the level of H2O2. In addition, TEM 
images of the NPs suspension in the 1.0 mM of H2O2 were taken at different time points to 
observe the evolution in the morphology of the NPs (Figure 3c). Already after 15 min, the 
NPs lost their original spherical shape, and some were swollen or partially degraded. This 
effect progressed overtime, showing a clear degradation of the particles after 60 min. OxiDEX 
is characterised by phenylboronic ester-groups, which might undergo hydrolysis in conditions 
of extreme pH.[29] For this reason, the physical stability of NPs was studied considering the 
physiological conditions of the GI tract (pH 1.2 for the gastric conditions and pH 6.8 for the 
intestinal environment, 37 °C). NPs showed a good physical stability in pH 6.8, whereas a 
partial degradation was observed in highly acidic conditions (pH 1.2) (Figure S5). 
 
Figure 3. (a) RIF release from OxiDEX NPs in PBS buffers with various concentrations of 
H2O2. Data represent mean ± S.D. (n = 3). (b) Appearance of the suspensions of RIF NPs in 
buffers with 1.0, 0.5, 0.25 and 0.1 mM of H2O2 (from left to right). (c) TEM images of the 







































































2.3. Characterization of nano-in-micro composites and in vitro drug release studies 
RIF NPs and CS-RIF NPs were encapsulated in a pH-responsive polymer MF grade of 
HPMCAS (HPMCAS-MF)[30] to form nano-in-micro composites by microfluidics, named as 
RIF NPs@MF and CS-RIF NPs@MF, respectively. The preparation process is schematically 
illustrated in Figure 1a. This method allowed the production of microparticles with spherical 
shape (Figure 4a) and monodispersed particle size distribution, with prevalent size of 53 ± 3 
μm (Figure S6). The distribution of NPs in the composites was studied by confocal 
microscopy (Figure 4a). To enable the visualization, NPs were labelled with fluorescein 
isothiocyanate (FITC) and the outer HPMCAS-MF polymer layer was labelled with Nile red. 
Confocal images showed an efficient encapsulation of NPs in the composites. Moreover, the 
prevalence of yellow in the merged image indicated a co-localization of NPs and matrix, with 
a homogeneous distribution of the NPs within the polymeric matrix. 
RIF NPs@MF and CS-RIF NPs@MF were immersed in simulated gastric fluid (SGF) at pH 
1.2 and afterwards in PBS at pH 6.8 to evaluate the pH-responsive dissolution behaviour. As 
reported in Figure 4b, composites kept their integrity after 2 h immersion in pH 1.2, showing 
no change of morphology. Differently, microparticles started to lose their shape already after 
5 min at pH 6.8, and they were completely degraded when the immersion time was prolonged 
to 2 h. These results suggest that nano-in-micro composites of based on HPMCAS-MF 
prepared by microfluidics are able to tolerate the harsh gastric conditions and to release the 







































































Figure 4. (a) FITC-labelled NPs were encapsulated in HPMCAS-MF with the addition of 
Nile red. The confocal images showed (from left to right) the Nile red, FITC and the overlay 
channels. In addition, the surface of the particles was observed by scanning electron 
microscope (SEM). (b) SEM images of RIF NPs@MF after immersion in SGF (pH 1.2) for 2 
h, and in PBS (pH 6.8) for 5 min and 2 h. (c) Drug release profiles of nano-in-micro 
composites (RIF NPs@MF and CS-RIF NPs@MF) and reference formulation consisted of 
pure drug encapsulated in HPMCAS MF (RIF@MF) first in SGF (pH 1.2) for 2 h and then in 
PBS (pH 6.8) with or without H2O2 for 6 h. Data represent mean ± S.D. (n = 3). 
 
In vitro drug release studies simulating the GI tract were carried out on the nano-in-micro 





































































by encapsulation of pure drug in the same enteric polymer HPMCAS-MF (RIF@MF), to 
better resemble the conventional commercial formulations. To evaluate the capability of the 
NPs to maintain the oxidation-responsive drug release after the encapsulation in the 
microcomposites, experiments in oxidative conditions (PBS with the addition of 1 mM of 
H2O2) were also performed. The release profiles (Figure 4c) showed that the MF matrix 
prevented the drug release at pH 1.2 in all samples. The release behaviour at pH 6.8 showed 
important differences: the drug was released immediately in the case of RIF@MF, while the 
RIF encapsulated in OxiDEX NPs was gradually released over 4 h. A controlled drug release 
is highly desired in IBD treatment, because it represents an advantage in terms of achieving 
the effective concentration required for local action and maintaining it over a sustained period 
of time. As expected, a very low drug amount (<10%) was released by the microcomposites 
in normal PBS buffer. It was interesting to notice that the coating with chitosan did not affect 
the dissolution behaviour. Additionally, to investigate the benefits of the nano-in-micro 
composites, in vitro release study of RIF NPs and CS-RIF NPs were also performed (Figure 
S7). In accordance with the previous results, the instability of OxiDEX in acidic pH led to 
more than 30% of RIF released in the gastric pH. In the second part of the study, performed at 
intestinal pH, the H2O2-responsive property of NPs was maintained, and a progressive drug 
release was observed only in oxidative conditions. As expected, no significant amount of drug 
was released in normal PBS. 
 
2.4. In vitro cytotoxicity studies 
The cytocompatibility of fabricated nanoparticles and nano-in-micro composites was 
evaluated on human colon carcinoma Caco-2 clone (C2BBe1) and human colon 
adenocarcinoma (HT29-MTX) cell lines, representing the enterocytes and the mucus-
producing goblet cells of the intestine, respectively.[31] The time points 6 and 24 h were 





































































the small intestine and the whole GI tract,[19] respectively. Cytotoxicity results are shown in 
Figure 5. OxiDEX NPs demonstrated to be safe for cells, even at very high concentrations 
(2000 μg ml-1), as cell viability was higher than 80% for both cell types for both time points, 
excluding the highest concentration of NPs incubated for 24 h with HT29-MTX cells. 
Compared to uncoated NPs, CS-NPs led to lower cell viability, probably because of the 
positive charge of the surface: however, the cell viability was still higher than 80% in all cases. 
Finally, the microcomposites showed the lowest viability. One possible explanation for this 
could be the very large amount of samples added in order to maintain fixed NPs concentration. 
Moreover, we should consider that in physiological conditions, HPMCAS would be 
solubilized (it is soluble at pH > 6), and consequently, it would be quickly eliminated by 
physiological clearance. Thus, in the case of the final microcomposites, the experimental 
conditions were not fully representative of the in vivo situation, because the polymer remained 






































































Figure 5. Viability of C2BBe1 and HT29-MTX cells after 6 and 24 h incubation with 
different concentration of NPs, CS-NPs, and nano-in-micro composites (NPs@MF). The 
concentration of NPs@MF was calculated based on the amount of encapsulated NPs. Data 
represent mean ± S.D. (n = 3), and the level of significance was set at the probabilities of *p < 
0.05, **p < 0.01, and ***p < 0.001 compared to the control (HBSS). 
 
2.5. Study of cell monolayers in oxidative conditions 
Preliminary tests showed that C2BBe1/HT29-MTX cell monolayers were responding in terms 
of increased ROS production to low concentrations (50 μM) of H2O2 and concentrations 
starting from 20 ng ml-1 of interleuchin-1β (IL-1β). Thus, they were used in combination to 
obtain monolayers in oxidative conditions. Treated monolayers exhibited higher ROS levels 
in the extracellular buffer, detected in the upper compartment, after 24 h incubation (Figure 
S8b), confirming the oxidative stress state. These monolayers were then compared with non-
treated ones in terms of membrane integrity and mucus layer characterization. IBD is reported 
to be associated with disruption of the intestinal epithelial layer, loss of barrier function and 
increased permeability.[32] Discordant data are reported regarding the mucus intestinal layer in 
IBD patients: increased mucus layer thickness was observed,[18] while dysregulated mucin 
production with loss of protective mucus layer was also reported.[33] In our cell model, the 
membrane integrity was slightly reduced in the oxidizing monolayers, as suggested by a 
modest, but still statistically significant drop in transepithelial electrical resistance (TEER) of 
20–25% (Figure 6a). This result was similar to the one obtained by Leonard et al. after 
treatment with IL-1β.[34] Moreover, the result is also in accordance with the permeability 
studies, where the drug permeability was higher in simulated oxidative conditions.  
The mucus layer distribution on C2BBe1/HT29-MTX cell monolayers was qualitatively 
studied by different staining methods. Figure 6b shows acid mucins stained by Alcian Blue, 





































































of both methods. Mucins were distributed on the monolayers in an irregular layer. The 
morphology of the mucus layer was similar for the oxidative conditions as well as for the 
control. The quantitative analysis (Figure 6c) showed no statistical differences in mucin 
content between stimulated and non-stimulated monolayers. The results suggested that the 
external mucus layer was not altered in oxidative conditions. Therefore, the mucoadhesive 
properties of NPs may be exploited to achieve better contact with the mucosal surface even in 
the case of oxidative stress conditions. 
 
Figure 6. (a) Membrane integrity attested by TEER measurement of cell monolayers in 
healthy and oxidizing conditions. The level of significance was set as **p < 0.01. (b) 
Qualitative mucus determination of cell monolayers in healthy and oxidative conditions. The 
scale bar is 200 µm for all images. (c) Mucus quantification in monolayers with periodic 
acid/Schiff stain colorimetric assay (mean ± SD, n = 3). 
 
2.6. Mucoadhesion of the particles to C2BBe1/HT29-MTX cell monolayers 
The interaction between NPs and intestinal cells was qualitatively studied by confocal laser 





































































AF 594) was used to stain the mucus and the cell membranes. It binds to sialic acid and N-
acetylglucosaminyl residues mainly localized in the mucus layer, which is particularly 
indicated when the objective is the evaluation of a mucoadhesive formulation. As can be seen 
in Figure 7, CLSM images showed no or minimal interactions between cells and OxiDEX 
NPs. The particles appeared as green, suggesting only a superficial adhesion to the cell 
monolayer, but no strong interaction with the mucus layer. Differently, for CS-coated NPs, 
more particles were observed on the cells. The larger amount of CS-NPs could be explained 
by the presence of CS on the NPs surface. The mucoadhesive properties of CS determined a 
high rate of interaction of CS-NPs with the co-cultured cells, thus decreasing the probability 
of washing away the particles during sample preparation. Electrostatic interactions of cationic 
CS with the negatively charged mucin are the main reason for CS strong mucosal adhesion.[35] 
Notably, most CS-NPs appeared as yellow, indicating a co-localization with the red-stained 
mucins of the mucus layer on the surface of the monolayer and, thus, a preferential 
accumulation of CS-NPs on the mucus layer on the intestinal membrane.  
 
Figure 7. 3D Confocal microscope images of C2BBe1/HT29-MTX monolayers treated with 
NPs and CS-NPs (250 μg ml-1) labelled with FITC after incubation with the cells at 37 °C for 





































































WGA-AF 594; green: FITC-labelled particles; and yellow: co-localization of NPs/CS-NPs 
and mucus.  
 
2.7. Drug permeability across C2bbe1/HT29-MTX cell monolayer  
After 21 days, the cell monolayers were completely differentiated and tight junction formed, 
as confirmed by TEER values stabilized at around 650 Ω.cm2 (Figure S8a). This model 
closely mimics the in vivo intestinal membrane.[36] Permeability curves and apparent 
permeability coefficients (Papp) are reported in Figure 8a,b, respectively. As observed from 
the permeation profiles, free RIF encapsulated in HPMCAS-MF showed the highest 
permeability, with a Papp of 5.41×10
-6. RIF encapsulated in NPs@MF and CS-NPs@MF had 
very low permeability (5.26×10-7 and 5.73×10-7, respectively). The Papp values of RIF were 
significantly decreased after encapsulation into the OxiDEX NPs, indicating that the NPs 
were effective to limit the drug absorption through intestinal membrane and therefore 
decrease the drug amount in the systemic circulation.  
Formulations were also tested with the addition of 1 mM of H2O2 in the donor compartment, 
to simulate an oxidative extracellular condition. This condition with high-oxidative medium 
allows a complete release of the drug after degradation of the H2O2-sensitive NPs. Comparing 
the Papp in the two conditions, the permeability resulted enhanced in the case of oxidative 
conditions for all samples. In particular, for RIF NPs@MF and CS-RIF NPs@MF, only in the 
presence of oxidizing species in the medium the drug was released and slowly permeated 
through the cell monolayer. The drug permeability was higher in oxidative conditions also in 
the case of RIF@MF, despite the absence of the H2O2-sentitive polymer, suggesting that the 
presence of H2O2 could influence the membrane integrity and contribute to increase drug 
permeation. Overall, the data indicate that the permeation of RIF may be drastically reduced 
by incorporation in OxiDEX NPs, especially in healthy conditions, representing an advantage 





































































After the permeability studies, the cell monolayers were observed under TEM (Figure 8c,d). 
The morphology of the cell monolayers was similar for all conditions, and the incubation with 
RIF NPs@MF and CS-RIF NPs@MF did not affect the appearance of the microvilli, 
indicating that the formulations have no toxic effects on the cell monolayers under the present 
experimental conditions tested. TEM images also showed some spherical dots (marked with 
red arrows) on the apical side of the monolayers near the microvilli, with dimensions quite 
similar to each other and in the range of the actual NPs (size around 100 nm). In particular, 
the dots seemed to be mainly attached to the cell monolayers or to remain in the close vicinity 
of the microvilli. It can be clearly noticed that more dots are present in the sample with CS-
NPs, compared to the one with NPs, suggesting that the CS coating influenced the 







































































Figure 8. (a) Permeation profiles of RIF across co-cultured C2BBe1/HT29-MTX (ratio of 
9:1) cell monolayers in normal or oxidizing (ox) conditions. The level of significance between 
the permeability of RIF@MF and the nano-in-micro composites (RIF NPs@MF and CS- RIF 
NPs@MF) in the same conditions were set at the probabilities of ***p < 0.001. (b) Apparent 
permeability coefficient (Papp) of RIF calculated from the drug permeation profiles. Data 
represent mean ± S.D. (n = 3). The level of significance was set the probability of ***p < 
0.001. TEM images of flat embedded sections of monolayers after permeability studies 
showing (c) RIF NPs and CS-RIF NPs interacting with the monolayers in healthy conditions 
and (d) with the monolayers simulating oxidizing conditions. 
 
3. Conclusion 
In this study, we developed nano-in-micro composites to achieve an oxidation-responsive 
delivery of RIF for IBD treatment. A phenylboronic esters-modified dextran (OxiDEX) was 
successfully employed to prepare RIF-loaded NPs, which showed highly H2O2-responsive 
degradation and controlled drug release in the presence of physiologically relevant (equal to 
or higher than 100 µM) H2O2 concentrations. The coating of NPs with CS significantly 
enhanced their stability in intestinal pH and their interactions with the intestinal mucosa, 
showing high mucoadhesive properties. Microfluidics allowed the encapsulation of NPs in 
HPMCAS, resulting in spherical and uniform microparticles able to protect the NPs from the 
harsh conditions of the stomach and to release them in the intestine. Compared to a traditional 
enteric formulation, the final composites showed ten times-decreased drug permeability 
across C2BBe1/HT29-MTX cell monolayer, indicating that OxiDEX NPs were effective to 
limit the drug permeation through intestinal epithelium, and therefore, representing an 
advantage in terms of unspecific absorption and systemic side effects. Overall, these results 







































































4. Experimental Section 
Preparation of OxiDEX nanoparticles: An oxidation-responsive dextran-modified polymer 
(OxiDEX) was synthesized using the procedure of Broaders et al.[7] with minor modifications 
and characterized by NMR. More detailed information can be found in the Supporting 
Information. OxiDEX NPs were prepared by nanoprecipitation method. OxiDEX (5 mg) was 
dissolved in dimethylsulfoxide (DMSO) (0.25 ml), and then added dropwise into the anti-
solvent (ethyl acetate, 2.5 ml) under magnetic stirring. The formed NPs were collected by 
centrifugation at 10000 rpm for 5 min washed with ethyl acetate and dried under vacuum at 
room temperature overnight. 
Drug loading: RIF loaded nanoparticles (RIF NPs) were prepared using the method described 
above, but adding RIF (2.5 mg) in the OxiDEX solution. The concentration of RIF in samples 
was determined by Agilent 1100 high performance liquid chromatography (HPLC, Agilent 
Technologies, USA) with a mobile phase composed of phosphoric acid (0.1%, pH 3.3) and 
acetonitrile (volume ratio 50:50) at a flow rate of 1mL min-1. A Gemini® 3 µm NX-C18 110 
Å column (Phenomenex, USA) was used as stationary phase. The injection volume of the 
samples was 10 µl and the detection wavelength was 293 nm. For the drug loading 
determination, 1 mg of NPs was accurately weighed and stirred in a mixture of 0.1 M of H2O2 
(0.5 ml) and acetonitrile (0.5 ml) for 2 h, until complete dissolution. The sample was 
centrifuged and the drug content in the supernatant was analyzed by HPLC. 
Coating of nanoparticles with chitosan: After preparation, NPs were coated with CS by 
physical adsorption method.[37] Medium viscosity chitosan (Mw=190000310000 Da, 75-85% 
deacetylated, Sigma-Aldrich, USA) was dissolved in 0.1 % acetic acid solution to obtain a 1% 
solution and the pH was adjusted to 5.5 by slowly adding sodium hydroxide solution. NPs and 
RIF-NPs were dispersed in 0.9 ml of MilliQ-water by sonication, 0.1 ml of CS solution was 





































































stirred with the CS solution for 1 h. CS-NPs and RIF-loaded CS-coated NPs (CS-RIF NPs) 
were collected by centrifugation and washed with MilliQ-water. 
Characterization of OxiDEX NPs: Size distribution and surface charge of NPs and RIF NPs 
before and after CS coating were determined by Zetasizer Nano ZS (Malvern Instruments Ltd, 
UK) in MilliQ-water (pH 7.4). Transmission electron microscopy (TEM; JEOL 1400, Japan) 
was used to observe the morphology of NPs before and during degradation study in presence 
of H2O2. TEM images were obtained with 80 kV acceleration voltage in bright-field mode. 
The chemical composition of dextran, OxiDEX, NPs, CS-NPs and pure CS was characterized 
by FTIR (Vertex 70, Bruker, USA). The FT-IR (KBr) spectra were recorded in the range of 
4000–650 cm−1 with a resolution of 4 cm−1 using OPUS 5.5 software. Differential scanning 
calorimetry (DSC; AG-DSC823e, Mettler Toledo, Switzerland) was performed on OxiDEX, 
NPs, pure drug and physical mixture (PM). Samples were heated from 25 °C to 250 °C under 
nitrogen flow at a heating rate of 10 °C min-1. Stability study was performed on drug loaded 
NPs and CS-NPs using Hanks’ balanced salt solution (HBSS) as buffer to mimic the intestinal 
medium (pH 6.8).[38] 
In vitro evaluation of oxidation-responsive degradation of the NPs: The response of OxiDEX 
NPs exposed to H2O2 and the consequent release of the drug were studied in vitro. RIF NPs 
(250 µg) were incubated in 1 ml of PBS buffer (pH 6.8, 37 °C) containing various 
concentrations (0, 0.1, 0.25, 0.5, 1.0 mM) of H2O2. At different time points, 100 µl of NPs 
suspension were withdrawn, centrifuged and the drug content in the supernatant was analyzed 
by HPLC. To study the stability of NPs in acidic conditions and the possible hydrolysis of 
NPs, quantitative experiments were conducted by measuring the absorbance of NPs-
containing aqueous solutions (pH 1.2 and pH 6.8, 37°C) at 500 nm at various time points. 
Microfluidic assembly of nano-in-micro composites: NPs were encapsulated by microfluidics 
in an enteric polymer, HPMCAS MF grade (HPMCAS-MF) with oil-in-water emulsion. The 





































































Precision Instruments, USA) assembled on a glass slide, as described elsewhere.[39] The 
injection rates of the inner oil fluid (HPMCAS-MF 10 mg ml-1 in ethyl acetate) and the outer 
fluid (2% w/v Poloxamer 407 aqueous solution, pH 4) were 2 ml h-1 and 20 ml h-1, 
respectively. RIF NPs and CS-RIF NPs were dispersed in the inner fluid before microfluidic 
process by tip sonication (weight ratio NPs:HPMCAS-MF 1:3), resulting in a homogeneous 
suspension, since OxiDEX NPs were highly stable in ethyl acetate. The formed droplets were 
collected in 1% Poloxamer 407 solution (pH 4.0). The solidified microparticles were collected 
by centrifugation, washed with MilliQ water (pH 4.0) and dried in a vacuum oven at 50 °C 
overnight. In addition to encapsulation of RIF NPs (NPs@MF) and CS-RIF NPs (CS-
NPs@MF), free drug was encapsulated (RIF@MF) to obtain a reference formulation. 
Labelling of nanoparticles with FITC: For confocal imaging, NPs were fluorescently labelled 
by loading of FITC. Briefly, FITC was added in the DMSO solution of the polymer to have a 
final concentration of OxiDEX and FITC of 20 mg ml-1 and 0.2 mg ml-1, respectively (ratio 
FITC:OxiDEX 1:100). The obtained solution was used to prepare labelled NPs using the same 
nanoprecipitation method.  
Characterization of nano-in-micro composites and in vitro drug release studies: To determine 
the distribution of the NPs into the microparticles of MF, CLSM was applied. FITC-labelled 
NPs were encapsulated in MF and Nile red was added as fluorescent dye to the inner fluid 
during the preparation of nano-in-micro composites. After microfluidic fabrication, the 
produced composites were arranged into 35 mm Petri-Dish with a thin bottom and imaged by 
CLSM (Leica SP5 II HCS A, Germany). 
The release profiles of the nano-in-micro composites were evaluated by using pH variation 
method (pH 1.2 and pH 6.8), as described in the European Pharmacopoeia. NPs@MF, CS-
NPs@MF (equivalent to 10 µg of RIF) were added to 1 ml of SGF (pH 1.2). After 2 h, 
particles were collected by centrifugation and resuspended in PBS buffer (pH 6.8) for 





































































points, 100 µl of the release medium were withdrawn, centrifuged to remove the solid 
particles and the amount of drug in the supernatant was quantified by HPLC. 100 µl of fresh 
medium were added to keep the volume constant. The morphology of nano-in-micro 
composites before and during the release study was examined by scanning electron 
microscopy (SEM, Hitachi S-4800, Japan). To investigate the benefits of the nano-in-micro 
composites, release studies were performed also with RIF NPs and CS-NPs, following the 
same experimental procedure. 
Cell culture: Human colon carcinoma Caco-2 clone C2BBe1 and human colon 
adenocarcinoma HT29-MTX were cultured in separate 75 cm2 culture flasks in high glucose 
(4.5 g l-1) Dulbecco’s modified Eagle’s medium (HyClone, Logan, UT) containing 10% of 
fetal bovine serum (Gibco, Invitrogen, USA), 1% (v/v) of L-glutamine, 1% (v/v) of 
nonessential amino acids, 100 IU ml-1 of penicillin, and 100 mg ml-1 of streptomycin 
(HyClone, Logan, UT). Cells were grown at 37°C in 5% of CO2 and 95% relative humidity 
and the cell medium changed every other day. 
In vitro cytotoxicity studies: Cytotoxicity of NPs, CS-NPs and nano-in-micro composites on 
cells was evaluated using CellTiter-Glo (Promega Corporation, USA). C2BBe1 and HT29-
MTX were separately seeded in 96-well plates at a density of 2 × 105 cells per ml and left to 
attach for 24 h. Then, the medium was discarded and cells were washed with 100 µl of 
Hanks’ balanced salt solution4-(2-hydroxyethyl)-1-piperazinethanesulfonic acid 
(HBSSHEPES, pH 7.4). Formulations were added to each well at a concentration of 50, 200, 
500, 1000 and 2000 µg ml-1 (NPs or equivalent) and incubated for 6 and 24 h. Afterwards, 
cells were washed twice with HBSSHEPES and the number of viable cells was quantified by 
addition of CellTiter-Glo. Luminescence was measured using a Varioskan Flash plate reader 
(Thermo Fisher Scientific, USA). HBSSHEPES without particles and Triton X-100 1% were 





































































Study of cell monolayers in oxidative conditions: Altered intestinal barrier integrity and 
significant modifications in mucus layer structure are typical in IBD active inflamed sites.[19] 
Therefore, monolayers in healthy and oxidative stress conditions were studied in terms of 
membrane integrity and mucus layer amount and distribution, after confirming the oxidative 
conditions by extracellular ROS measurement. More detailed information can be found in the 
Supporting Information.  
C2BBe1/HT29-MTX cell monolayer: cells were seeded on 12-Transwell cell culture inserts at 
a seeding density of 70,000 cells per cm2 with C2BBe1 and HT29-MTX cells in a ratio of 9:1, 
the medium was replaced every other day until the cell monolayer was formed after 21 days. 
TEER was measured all over the 21 days to control the development of tight junctions. 
Mucoadhesion of the particles to C2BBe1/HT29-MTX cell monolayers: Cell monolayers were 
washed with HBSSHEPES, then 200 µL suspension of labelled particles in HBSSHEPES 
(250 µg ml-1) was added and incubated for 4 h at 37 °C. After incubation, the monolayerss 
were washed twice with HBSSHEPES (pH 7.4) to remove the particles not attached and 
fixed with 4% paraformaldehyde at room temperature for 15 min. Wheat Germ Agglutinin-
Alexa Fluor 594 conjugate (WGA-AF 594) (10 μg mL−1) was incubated 10 minutes to stain 
the mucus. After washing, the Transwell filter was excised, embedded in a mounting medium 
containing DAPI and mounted on glass slides for confocal imaging. The particle–cell 
interactions were observed using CLSM (Leica SP5, Leica Microsystems, Germany). 
Drug permeability across C2BBe1/HT29-MTX cell monolayer: The permeability of RIF 
across the cell monolayers was investigated from the apical (0.5 mL) to basolateral direction 
(1.5 mL) at 37 °C with shaking at 100 rpm. HBSSHEPES buffer solution pH 7.4 was used in 
the received compartment, whereas HBSSHEPES buffer (pH 6.8) with or without 1 mM of 
H2O2 was employed in the donor compartment to simulate healthy and oxidative extracellular 





































































concentration of 6 μg ml-1. At specific time points (15, 30, 60, 90, 120 and 180 min) 100 µl of 
the release medium were withdrawn from the basolateral part and replaced with fresh medium. 
The amount of drug permeated in the basolateral compartment was quantified by HPLC and 
the Papp was calculated.
[40] The experiments were carried out in triplicate. 
Flat embedding TEM: After permeability studies, the cell monolayers were fixed with 2.5% 
glutaraldehyde (Sigma-Aldrich, USA) in 0.1 M of phosphate buffer saline (PBS) (pH 7.4) for 
20 min at room temperature. Then, the wells were washed twice with sodium cacodylate 
buffer (NaCac) for 3 min. After that, the cell monolayers were post-fixed with 1% of osmium 
tetroxide in 0.1 M of NaCac buffer (pH 7.4) and then dehydrated and embedded in epoxy 
resin. Ultrathin sections (60 nm) were cut perpendicularly to the inserts, post-stained with 
uranyl acetate and lead citrate, and examined with TEM. 
Statistical Analysis: All results were expressed as mean ± standard deviation (S.D.). Analysis 
of variance (ANOVA) followed by the Bonferroni post hoc test (GraphPadPrism, GraphPad 
software Inc., CA, USA) was used to analyse the data and the level of significance was set at 
the probabilities of *p < 0.05, **p < 0.01 and ***p < 0.001. 
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Supporting Information is available from the Wiley Online Library or from the author. 
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An advanced nano-in-micro composite is successfully prepared with a phenylboronic 
esters-modified dextran (OxiDEX) to achieve an oxidation-responsive drug delivery for the 
therapy of inflammatory bowel disease. H2O2-selective OxiDEX degradation and consequent 
drug release are demonstrated. The composite limits the drug permeation through intestinal 
epithelium providing a promising approach to limit unspecific absorption and systemic side 
effects. 
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pH and reactive oxygen species-sequential responsive nano-in-micro composite for 
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